Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in advanced hepatocellular carcinoma
NCT05101629Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Started May 2022; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05101629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101629.